Lee’s Pharm is a research-driven and market-oriented biopharmaceutical company with 30 years of operation in the pharmaceutical industry in China. The Group is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China. The Company has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm focuses on several key disease areas such as cardiovascular, woman health, pediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing of development, commercialization, and manufacturing rights from various United States, European and Japanese companies. For more information, please visit www.leespharm.com.
Laboratorios PISA SA de CV
PiSA® Farmacéutica is a 100% Mexican company with 80 years of history, developing comprehensive products and services for both the public and private healthcare sectors in Mexico, the United States, Latin America, and the Caribbean. For more than seven decades, PiSA® Farmacéutica has experienced consistent growth, driven by its human capital. We are committed to excellence, fully aware that each of our actions and activities is carried out in fulfillment of our purpose: “A Life in the Service of Life.” At PiSA® Farmacéutica, we are recognized for our production capacity and extensive experience in the Mexican and Latin American markets; this has enabled us to set the standard for our growth and international expansion.
Laboratorio Elea
Elea Phoenix is a top Argentinean Laboratory that has been researching and developing trustworthy and innovative medicines for a wide range of medical specialities since 1939. With leading trademarks, research and development projects of our own and licences from International renowed Companies. With Industrial Manufacturing Plants that operate efficiently, a wide distribution network, we focus firmly on the development of new products, in the following areas: Oncology, Biotechnology, Cardiology, Neuropsychiatry, Woman`s Health. Laboratorio ELEA is currently working with monoclonal antibodies, recombinant proteins, synthetic peptides, therapeutic vaccines for oncology. We are the first Company to launch a monoclonal antibody in 1997 , and in 2014 we launched the first Biosimilar mAb for Rituximab and Bevacizumab in 2016 . Now with have a potfolio of over 600 products, ranking 2nd for OTC/RX products. We have a strong portfolio in Biotech, launching Biopharmaceutical products every 2 years. | Elea is a top Argentinean Laboratory that has been researching and developing trustworthy and innovative medicines for a wide range of medical specialities since 1939. With leading trademarks, research and development projects of our own and licences from International renowed Companies. With Industrial Manufacturing Plants in Argentina and Latam that operate efficiently, a wide distribution network in several countries, we focus firmly on the development of new products, in the following areas: Oncology, Biotechnology, Cardiology, Neuropsychiatry, Woman`s Health. Laboratorio ELEA is currently working with monoclonal antibodies, recombinant proteins, synthetic peptides, therapeutic vaccines for oncology. We are the first Company to launch a monoclonal antibody in 1997 , and in 2014 we launched the first Biosimilar mAb for Rituximab and Bevacizumab in 2016 . Now with have a potfolio of over 600 products, ranking 2nd for OTC/RX products. We have a strong portfolio in Biotech, launching Biopharmaceutical products every 2 years. | We are an Argentine pharmaceutical company with more than 80 years of experience, dedicated to the research, development, and manufacturing of quality medicines for various medical specialties. Since 1939, we have stood out for offering innovative solutions that improve the health and quality of life of people, both in Argentina and throughout Latin America. ✅ We integrate our own research and development, alliances with important international laboratories and high-tech production plants, ensuring that innovation is present in every stage of our process. All this, together with an extensive distribution network, positions us among the leaders in the Argentine pharmaceutical market. Our main therapeutic areas are: Women’s Health – Urology – Anti-infectives – Respiratory – Internal Medicine – Ophthalmology – Neurosciences – Cardiometabolism – Osteoarticular – Gastroenterology – Oncology and Biotechnology – HIV – Over-the-Counter. We have a strong portfolio of Biopharmaceutical products in the market (EPO, Rituximab, Bevacizumab, Trastuzumab, Adalimumab, Pembrolizumab, Racotumomab, Nimotuzumab).
KIOMED PHARMA
Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a commercial-stage biotech spinout from KitoZyme, develops a unique pipeline of medical devices that address unmet medical needs in high-impact pathologies and major social burdens such as invalidating OsteoArthritis, Skin Aging and Ophthalmology. KiOmed Pharma’s innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative. | Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a commercial-stage biotech spinout from KitoZyme and the University of Liege, has developpeds a unique pipeline of medical devices that address unmet medical needs in high-impact pathologies and major social burdens such as invalidating OsteoArthritis, Skin Aging and Ophthalmology. KiOmed Pharma’s innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative. KioMedine-vs-one, the company’s first product, currently commercialized in 15 countries, is a unique fluid implant indicated for the symptomatic treatment of knee osteoarthritis via a single intraarticular injection, providing up to 12 months symptom relief. KioMedine-vs-one is targeted to refractory knee OA patients, who do not respond well to existing treatments and constitutes for these patients a cost-effective alternative to TKR surgery, that can potentially be delayed or avoided.
JSS Medical Research
JSS Medical Research Inc., is a full-service clinical research organization (CRO) with strong academic affiliations that was founded in the mid-1980s by Dr. John S. Sampalis, CEO/CSO, a tenured Professor in the Faculty of Medicine of McGill University and the University of Montreal. All senior scientific members of JSS Medical Research have training in clinical research and epidemiology, and are affiliated with McGill University, University of Montreal or Laval University. Through our corporate head office, located in Montreal, Canada, regional hubs in Bogotá (Colombia) and New Delhi (India), and our global network of partners, JSS has successfully conducted over 1100+ multi-therapeutic clinical studies in 58 countries in the last 10 years. we can conduct clinical research in North America, Latin America, Europe, the Middle East and Asia. The services offered by JSS Medical Research cover the entire spectrum of clinical research from study conception, design, execution, data analysis and dissemination of results. The staff of JSS Medical Research includes clinical epidemiologists, physicians, biostatisticians, project managers, quality assurance experts, monitors, medical writers and information technology experts. One of our distinguishing attributes is our methodological knowledge and expertise in the design and execution of clinical studies. Globally, JSS Medical Research has conducted over 1200 projects. Specifically, within the Americas (mainly USA and Canada), 522 were completed with • 26 Phase I trials, • 92 Phase II, • 119 Phase III trials, • 263 were Phaser IV – Post-Marketing Observational Studies or Health Economic and Outcome Research projects, • 27 Medical device Studies, and • 18 Ministry of Health Regulatory Submissions in the LATAM Region. The therapeutic areas covered in these projects include – but are not limited to –autoimmune disorders, cardiovascular disease, CNS/psychiatric conditions, dermatology, endocrinology (diabetes), gastroenterology, infectious diseases (including COVID/HIV/hepatitis), medical devices, pain management and trauma, obesity, oncology/hematology, ophthalmological diseases, respiratory conditions, rheumatology (arthritis/OA), transplantation, women’s health and vaccines. www.JSSresearch.com
Inventage Lab Inc
.. | Inventage Lab(KOSDAQ: 389470) is a clinical-stage biopharmaceutical company specializing in drug delivery system, especially the development of long-acting injectables and lipid nanoparticles using a microfluidic manufacturing platform. IVL-DrugFluidic® platform enables the production of high-quality of microsphere based long-acting injectable formulations by eliminating initial drug over-release and ensuring the mass production of uniform microspheres. It has been successfully applied to veterinary medicine and clinical trials for androgenic alopecia, dementia, and addiction treatments. The platform also supports drug re-discovery and partnerships for novel drug formulations with partnering pharmaceutical companies. Harnessing our HANDYGENE™ system, this platform focuses on developing lipid nanoparticles (LNPs) for vaccines and gene therapies. Inventage Lab also offers services, including LNP formulation and non-clinical and clinical sample production, while diversifying its business through selling and subscribing to its LNP manufacturing equipment.
Indian Immunologicals Ltd
Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player, conceptualizing and executing the products journey from bench at the R&D lab to its sale at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in these two segments, we recognized both, the inter-dependence, and inter-linkages of the two segments and as a result have been spearheading the One Health initiative since a long time. IIL had its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturer of the country and the region. We ventured into manufacturing human vaccines by 1998 on specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of nine new vaccine candidates. We have a huge pipeline of vaccine for Animal Health segment. We are one of the leading manufacturers of Pet Vaccines. IIL has four world class manufacturing facilities spread across India and New Zealand. IIL collaborates with several leading pharma/vaccines companies within India and outside for manufacturing and research collaborations. Our capabilities and experience in handling projects across varied platforms technologies, across varied scales (small to very high) enable us to offer both flexibility and confidence to our partners for a smooth execution. We solicit cooperation proposals to build synergistic relationships. | Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player that conceptualizes and executes the products journey from bench at the R&D lab to its use at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in the two segments, we recognized both, the interdependence, and interlinkages of the two segments and as a result have been spearheading the One Health initiative for a long time. IIL has its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturers of the region. After starting off an animal vaccine manufacturer, we started manufacturing human vaccines in 1998 on a specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of five new vaccine candidates. We are currently serving and touching lives in more than fifty (60) countries by exporting both our animal health and human health products. We have four world class manufacturing units spear across India and New Zealand. IIL, through its state-of-the-art facilities, collaborates with several leading pharma/vaccines companies within India and outside.
IBEX Therapeutics SA
Ibex Therapeutics is Swiss biotech company developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis, debilitating conditions which very often occur as adverse effect of cancer chemo- and radiotherapy and affects the care journey and the quality of life of cancer patients. A de-risked and short path to registration and commercialization by 2028, as validated by the German health authority BfArM: the lead product (containing 2 water-based plant extracts) is produced in GMP conditions and has confirmed its efficacy and safety in a pilot study in cancer patients. Ibex Tx is raising CHF 3 million, of which 1.0+ million has already received soft commitments, with the largest part of the proceeds to fund a final pivotal clinical study, and some portfolio extensions (including a probiotic to synergize with the oral topical therapy, and a spray presentation to augment portability and convenience of use by ambulatory patients). Strong market fundamentals: sustained medical need (increasing incidence of cancer and use of mucositis-inducing therapies), and absence of reference treatment. Further, Ibex Tx will register the product in several geographies (EU, USA, Asia, BRICS), and sign licensing agreements to ensure efficient commercialization outside of Switzerland.
I+MED S.COOP.
i+Med is a biomedical engineering company devoted to the research, development and manufacturing of biomedical devices and innovative medicines with high added value. We are knowledge generators. A cooperative of scientists positioned as one of the world leaders in the field of nanohydrogels and controlled release. We are specialists in the development of smart nanohydrogels and controlled release of active ingredients. We apply our expertise around different technologies, supported by our 5 patents, thus customising different solutions tailored to our client’s needs. | i+Med is a biomedical engineering company devoted to the research, development and manufacturing of biomedical devices and innovative medicines with high added value. We are knowledge generators. A cooperative of scientists positioned as one of the world leaders in the field of controlled release systems, turnable hydrogels and nanohydrogels. We are specialists in the development of smart nanohydrogels and controlled release of active ingredients such as different APIs, peptides or bio. We apply our expertise around different technologies, supported by our patents, thus customising different solutions tailored to pharmaceutical companies needs. Our headquarters are located in Vitoria, Basque Country, in the north of Spain. In our facilities we develop an active R&D activity for third parties and manufacture high added value medical devices for traumatology, aesthetics, ophthalmology and dermatology that we distribute worldwide. We have a team of more than 150 employees focused on generating innovative biomedical solutions to cover unmet medical needs.
Hypera Pharma
A giant in the brazilian market, Hypera Pharma is the largest brazilian pharmaceutical company, owner of a strong portfolio of non-replicable leading brands in Brazil including 21 power brands. Hypera is looking for strategic players to partner in improving our portfolio with novel pharma and innovative technologies. | Hypera Pharma is one of the biggest and most diversified pharmaceutical companies in Brazil. It’s present in all relevant segments of the retail pharmaceutical sector in Brazil, with leadership in several product categories. The company offers high-quality products, and keeps investing in innovation to grow in a sustainable way. The strength of the Company in the pharmaceutical market is supported by a large-scale and low-cost operation based in the largest pharmaceutical operating complex in Latin America, located in Anápolis, Goiás. It is a 120,000-square meter structure with more than 9,000 employees. Annually it produces more than 650 million solid doses, 20 million units of injectable drugs and eye drops, more than 250 million units of vitamins and 300 million units of liquids, creams, oils and lotions. To support constant innovation in its business, the Company created in 2017 Hynova, the most modern pharmaceutical research center in Brazil, which houses a team of highly qualified professionals, masters and doctors for the development of medicines, dermocosmetics and nutraceuticals, using cutting-edge technology to be a pioneer in Brazil. The Company also has a broad national sales and distribution structure. Its products are distributed throughout Brazil, directly to retailers, or indirectly through distributors and wholesalers. Founded in 2001 as Hypermarcas, its corporate name changed in 2017 to Hypera Pharma, evidencing the Company’s new focus in the pharmaceutical market. It is listed in B3’s Novo Mercado since 2008 and currently employs around 10,000 people.